Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
REGULATORY
MHLW Unveils Gx Pricing Plans, Wants to Rectify Distortion by Cutting Oral AG Price: Chuikyo
As it sets out a flurry of reform proposals on the pricing of new drugs and off-patent products, the government plans to keep intact the current rules for first generics and first biosimilars for now. However, price revision rules for…
To read the full story
Related Article
- MHLW Proposes Pricing Support for Startups: Chuikyo
November 28, 2017
- CEA-Based Price Tweak Likely to Cover Premium Portion, Not Total Price; Price Raise Also Proposed: Chuikyo
November 28, 2017
- MHLW Proposes Expansion of “Essential Drug” Category to Include Crude Drugs, Ointment Bases, Local Dental Anesthetics and More: Chuikyo
November 28, 2017
- MHLW Proposes Tacking Premiums on Total Drug Price under Cost Calculation Formula: Chuikyo
November 27, 2017
- New Price Cut Scheme for Off-Patent Meds Proposed with Mitigation Plans, but Payer Reps Say Gx Transition Too Slow: Chuikyo
November 24, 2017
- Quarterly Market Expansion Re-Pricing Pitched for 35-Plus Billion Yen Products: Chuikyo
November 24, 2017
- MHLW Proposes Post-Launch Foreign Price Adjustments: Chuikyo
November 24, 2017
- Draft Outline of Drug Pricing Overhaul Unveiled at Chuikyo; De-Facto Shrinkage for Price Maintenance Scheme Proposed
November 24, 2017
- Chuikyo Agrees to Define Scope of Off-Year Re-Pricing by 2020-End for 1st Off-Year Revision in April 2021
November 22, 2017
REGULATORY
- LDP Leans Towards “Special Charges” for OTC-Like Drugs, Not Coverage Removal
December 15, 2025
- Ishin Urges “Special Charge” Scheme for OTC-Like Drugs, Eyes FY2026 Launch
December 15, 2025
- Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests
December 15, 2025
- LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…